CGC vs. ABCL, REPL, COLL, RCKT, EOLS, PHVS, AVBP, COGT, OCS, and BCYC
Should you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include AbCellera Biologics (ABCL), Replimune Group (REPL), Collegium Pharmaceutical (COLL), Rocket Pharmaceuticals (RCKT), Evolus (EOLS), Pharvaris (PHVS), ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), Oculis (OCS), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry.
Canopy Growth vs.
Canopy Growth (NASDAQ:CGC) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, institutional ownership, risk and profitability.
3.3% of Canopy Growth shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 1.3% of Canopy Growth shares are owned by company insiders. Comparatively, 28.0% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Canopy Growth presently has a consensus price target of $2.00, indicating a potential upside of 23.84%. AbCellera Biologics has a consensus price target of $8.33, indicating a potential upside of 162.47%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than Canopy Growth.
Canopy Growth has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500.
In the previous week, AbCellera Biologics had 7 more articles in the media than Canopy Growth. MarketBeat recorded 9 mentions for AbCellera Biologics and 2 mentions for Canopy Growth. AbCellera Biologics' average media sentiment score of 0.64 beat Canopy Growth's score of 0.03 indicating that AbCellera Biologics is being referred to more favorably in the news media.
AbCellera Biologics received 34 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 76.06% of users gave AbCellera Biologics an outperform vote while only 19.23% of users gave Canopy Growth an outperform vote.
AbCellera Biologics has lower revenue, but higher earnings than Canopy Growth. AbCellera Biologics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
Canopy Growth has a net margin of -156.98% compared to AbCellera Biologics' net margin of -533.32%. AbCellera Biologics' return on equity of -15.73% beat Canopy Growth's return on equity.
Summary
AbCellera Biologics beats Canopy Growth on 14 of the 18 factors compared between the two stocks.
Get Canopy Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Canopy Growth Competitors List
Related Companies and Tools
This page (NASDAQ:CGC) was last updated on 2/20/2025 by MarketBeat.com Staff
Free CGC Stock Alerts